- -

Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study

RiuNet: Institutional repository of the Polithecnic University of Valencia

Share/Send to

Cited by

Statistics

Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study

Show simple item record

Files in this item

dc.contributor.author Lucidi, Paola es_ES
dc.contributor.author Porcellati, Francesca es_ES
dc.contributor.author Rossetti ., Paolo es_ES
dc.contributor.author Candeloro, Paola es_ES
dc.contributor.author Cioli, Patrizia es_ES
dc.contributor.author Marzotti, Stefania es_ES
dc.contributor.author Andreoli, Anna Marinelli es_ES
dc.contributor.author Fede, Raffaela es_ES
dc.contributor.author Bolli, Geremia B. es_ES
dc.contributor.author Fanelli, Carmine G. es_ES
dc.date.accessioned 2013-11-25T14:39:50Z
dc.date.issued 2011
dc.identifier.issn 0149-5992
dc.identifier.uri http://hdl.handle.net/10251/33977
dc.description.abstract OBJECTIVE-To compare the pharmacokinetics and pharmacodynamics of NPH, glargine, and detemir insulins in type 2 diabetic subjects. RESEARCH DESIGN AND METHODS-This study used a single-blind, three-way, cross-over design. A total of 18 type 2 diabetic subjects underwent a euglycemic clamp for 32 h after a subcutaneous injection of 0.4 units/kg at 2200 h of either NPH, glargine, or detemir after 1 week of bedtime treatment with each insulin. RESULTS-The glucose infusion rate area under the curve(0-32 h) was greater for glargine than for detemir and NPH (1,538 +/- 688; 1,081 +/- 785; and 1,170 +/- 703 mg/kg, respectively; P < 0.05). Glargine suppressed endogenous glucose production more than detemir (P < 0.05) and similarly to NPH (P = 0.16). Glucagon, C-peptide, free fatty acids, and beta-hydroxy-butyrate were more suppressed with glargine than detemir. All 18 subjects completed the glargine study, but two subjects on NPH and three on detemir interrupted the study because of plasma glucose >150 mg/dL. CONCLUSIONS-Compared with NPH and detemir, glargine provided greater metabolic activity and superior glucose control for up to 32 h. es_ES
dc.language Inglés es_ES
dc.publisher American Diabetes Association es_ES
dc.relation.ispartof Diabetes Care es_ES
dc.rights Reserva de todos los derechos es_ES
dc.title Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study es_ES
dc.type Artículo es_ES
dc.embargo.lift 10000-01-01
dc.embargo.terms forever es_ES
dc.identifier.doi 10.2337/dc10-1911
dc.rights.accessRights Cerrado es_ES
dc.contributor.affiliation Universitat Politècnica de València. Instituto Universitario de Automática e Informática Industrial - Institut Universitari d'Automàtica i Informàtica Industrial es_ES
dc.description.bibliographicCitation Lucidi, P.; Porcellati, F.; Rossetti ., P.; Candeloro, P.; Cioli, P.; Marzotti, S.; Andreoli, AM.... (2011). Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study. Diabetes Care. 34(6):1312-1314. doi:10.2337/dc10-1911 es_ES
dc.description.accrualMethod S es_ES
dc.relation.publisherversion http://dx.doi.org/10.2337/dc10-1911 es_ES
dc.description.upvformatpinicio 1312 es_ES
dc.description.upvformatpfin 1314 es_ES
dc.type.version info:eu-repo/semantics/publishedVersion es_ES
dc.description.volume 34 es_ES
dc.description.issue 6 es_ES
dc.relation.senia 220400


This item appears in the following Collection(s)

Show simple item record